Correction: Predominant Expression of CCL2 at the Tumor Site of Prostate Cancer Patients Directs a Selective Loss of Immunological Tolerance to CCL2 That Could Be Amplified in a Beneficial Manner [CORRECTIONS]

from The Journal of Immunology current issue http://ift.tt/2HN0fbZ